Publikationen 2008

  1. Balgobind BV, van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER, Reinhardt D, Horstmann M, Kaspers GJ, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM, Meijerink JP: Leukemia associated NF1 inactivation in pediatric T-ALL and AML patients lacking evidence for neurofibromatosis. Blood 2008;111:4322-4328. www.ncbi.nlm.nih.gov/pubmed/18172006
  2. Chapuy B, Koch R, Radunski U, Corsham S, Cheong N, Inagaki N, Ban N, Wenzel D, Reinhardt D, Zapf A, Schweyer S, Kosari F, Klapper W, Truemper L, Wulf GG: Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 2008;22:1576-1586. www.ncbi.nlm.nih.gov/pubmed/18463677
  3. Creutzig U: Epidemiologie und Pathogenese; in Ehninger G, Link H, Berdel WE, (eds): Akute myeloische Leukämie (Pathophysiologie, Diagnostik, Therapie, Prognose). Köln, Deutscher Ärzte-Verlag, 2008, pp 228-238.
  4. Creutzig U, Zimmermann M, Dworzak M, Stary J, Reinhardt D, for the AML-BFM Study Group: Improvement of Strategies and Experience Within the AML-BFM Therapy Trials. Ann Hematol 2008;87:S47-S50.
  5. Creutzig U, Buchner T, Sauerland MC, Zimmermann M, Reinhardt D, Dohner H, Schlenk RF: Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer 2008;112:562-571. www.ncbi.nlm.nih.gov/pubmed/18076087
  6. de Jonge HJ, Weidenaar AC, ter Elst A, Boezen HM, Scherpen FJ, Bouma-Ter Steege JC, Kaspers GJ, Goemans BF, Creutzig U, Zimmermann M, Kamps WA, de Bont ES: Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clin Cancer Res 2008;14:924-930. www.ncbi.nlm.nih.gov/pubmed/18245556
  7. Goemans BF, Zwaan CM, Vijverberg SJ, Loonen AH, Creutzig U, Hahlen K, Reinhardt D, Gibson BE, Cloos J, Kaspers GJ: Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia. Leukemia 2008;22:2284-2285. www.ncbi.nlm.nih.gov/pubmed/18563175
  8. Hasle H, Abrahamsson J, Arola M, Karow A, O'Marcaigh A, Reinhardt D, Webb DK, van Wering E, Zeller B, Zwaan CM, Vyas P: Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia 2008;22:1428-1430. www.ncbi.nlm.nih.gov/pubmed/18059480
  9. Hess CJ, Ameziane N, Schuurhuis GJ, Errami A, Denkers F, Kaspers GJ, Cloos J, Joenje H, Reinhardt D, Ossenkoppele GJ, Zwaan CM, Waisfisz Q: Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol 2008;30:299-306. www.ncbi.nlm.nih.gov/pubmed/18607065
  10. Klingebiel T, Reinhardt D, Bader P: Place of HSCT in treatment of childhood AML. Bone Marrow Transplant 2008;42 Suppl 2:S7-S9. www.ncbi.nlm.nih.gov/pubmed/18978749
  11. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, Pekrun A, Macakova-Reinhardt K, Reinhardt D: Treatment and prognostic impact of transient leukemia in neonates with Down's syndrome. Blood 2008;111:2991-2998. www.ncbi.nlm.nih.gov/pubmed/18182574
  12. Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, Villeval JL, Reinhardt D, Landman-Parker J, Michaux L, Dastugue N, Baruchel A, Vainchenker W, Bourquin JP, Penard-Lacronique V, Bernard OA: Activating mutations in human acute megakaryoblastic leukemia. Blood 2008. www.ncbi.nlm.nih.gov/pubmed/18755984
  13. Messerer D, Engel J, Hasford J, Schaich M, Ehninger G, Sauerland C, Buchner T, Schumacher A, Krahl R, Niederwieser D, Krauter J, Ganser A, Creutzig U, Dohner H, Schlenk RF: Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica 2008;93:826-833. www.ncbi.nlm.nih.gov/pubmed/18469349
  14. Meyer LH, Queudeville M, Eckhoff SM, Creutzig U, Reinhardt D, Karawajew L, Ludwig WD, Stahnke K, Debatin KM: Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML. Blood 2008;111:2899-2903. www.ncbi.nlm.nih.gov/pubmed/18083847
  15. Schrappe M, Creutzig U: Akute lymphoblastische Leukämie (ALL) und akute myeloische Leukämie (AML); in Deutsche Krebsgesellschaft - C.Garbe et al., (ed): Kurzgefasste interdisziplinäre Leitlinien 2008 (Empfehlungen zur Diagnostik und Therapie maligner Erkrankungen). München, Zuckschwerdt Verlag, 2008, p 263ff.
  16. Stary J, Baumann I, Creutzig U, Harbott J, Michalova K, Niemeyer C: Getting the numbers straight in pediatric MDS: distribution of subtypes after exclusion of down syndrome. Pediatr Blood Cancer 2008;50:435-436. www.ncbi.nlm.nih.gov/pubmed/17455316
  17. Zwaan MC, Reinhardt D, Hitzler J, Vyas P: Acute leukemias in children with Down syndrome. Pediatr Clin North Am 2008;55:53-70, x. www.ncbi.nlm.nih.gov/pubmed/18242315
Suchen
Benutzeranmeldung